Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FLAsH-IV-AML: A Phase I/II Multi-center Study to Assess the Tolerability and Efficacy of the Addition of Hydroxyurea to Salvage Treatment With Fludarabine, Ara-C, Idarubicin and Venetoclax for Adults With Relapsed or Refractory Acute Myeloid Leukemia

NCT07766850 is registered in ClinicalTrials.gov with Christer C Nilsson as lead sponsor.

NCT NCT07766850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07766850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FLAsH-IV-AML: A Phase I/II Multi-center Study to Assess the Tolerability and Efficacy of the Addition of Hydroxyurea to Salvage Treatment With Fludarabine, Ara-C, Idarubicin and Venetoclax for Adults With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Christer C Nilsson
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
September 30, 2034
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

r/r aml